Literature DB >> 33804446

Antibacterial and COX-2 Inhibitory Tetrahydrobisbenzylisoquinoline Alkaloids from the Philippine Medicinal Plant Phaeanthus ophthalmicus.

Hilbert D Magpantay1, Ivane N Malaluan2,3, Joe Anthony H Manzano2,4, Mark Tristan Quimque2,5, Kirstin Rhys Pueblos2,5, Natalija Moor6, Simon Budde6, Porferio S Bangcaya7, Demi Lim-Valle8, Hans-Martin Dahse9, Abbas Khan10, Dong-Qing Wei10,11,12, Grecebio Jonathan D Alejandro13, Allan Patrick G Macabeo2.   

Abstract

Phaeanthus ophthalmicus (Roxb. ex G.Don) J.Sinclair (previously known as P. ebracteolatus (Presl) Merr) is a Philippine medicinal plant occurring as evergreen shrub in the lowland forests of Luzon islands. It is used traditionally by Filipinos to treat bacterial conjunctivitis, ulcer and wound infections. Based on previous investigations where cyclooxygenase-2 (COX-2) functions as immune-linked factor in infectious sensitivities to bacterial pathogens by triggering pro-inflammatory immune-associated reactions, we investigated the antimicrobial and COX inhibitory activities of the extracts and tetrahydrobisbenzylisoquinoline alkaloids of P. ophthalmicus in vitro and in silico to validate its ethnomedicinal uses. Thus, the dichloromethane-methanol (DCM-MeOH) crude extract and alkaloid extracts exhibiting antibacterial activities against drug-resistant bacterial strains such as methicillin-resistance Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Klebsiella pneumoniae + CRE and Pseudomonas aeruginosa + MBL afforded (+)-tetrandrine (1) and (+)-limacusine (2) as the major biologically active tetrahydrobisbenzylisoquinoline alkaloidal constituents after purification. Both tetrahydrobisbenzylisoquinoline alkaloids 1 and 2 showed broad spectrum antibacterial activity with strongest inhibition against the Gram-negative bacteria MβL-Pseudomonas aeruginosa Klebsiella pneumoniae + CRE. Interestingly, the alkaloid limacusine (2) showed selective inhibition against ovine COX-2 in vitro. These results were ascertained by molecular docking and molecular dynamics simulation experiments where alkaloid 2 showed strong affinity in the catalytic sites of Gram-negative bacterial enzymes P. aeruginosa elastase and K. pneumoniae KPC-2 carbapenemase (enzymes involved in infectivity mechanisms), and of ovine COX-2. Overall, our study provides credence on the ethnomedicinal use of the Philippine medicinal plant P. ophthalmicus as traditional plant-based adjuvant to treat bacterial conjunctivitis and other related infections. The antibacterial activities and selective COX-2 inhibition observed for limacusine (2) point to its role as the biologically active constituent of P. ophthalmicus. A limited number of drugs with COX-2 inhibitory properties like celecoxib also confer antibacterial activity. Thus, tetrahydrobisbenzyl alkaloids, especially 2, are promising pharmaceutical inspirations for developing treatments of bacterial/inflammation-related infections.

Entities:  

Keywords:  COX-2; Phaeanthus ophthalmicus; anti-inflammatory; antibacterial; ethnomedicinal; limacusine; medicinal plants; molecular docking; molecular dynamics simulation; tetrahydrobisbenzylisoquinoline alkaloids

Year:  2021        PMID: 33804446      PMCID: PMC7999448          DOI: 10.3390/plants10030462

Source DB:  PubMed          Journal:  Plants (Basel)        ISSN: 2223-7747


  55 in total

1.  The Amber biomolecular simulation programs.

Authors:  David A Case; Thomas E Cheatham; Tom Darden; Holger Gohlke; Ray Luo; Kenneth M Merz; Alexey Onufriev; Carlos Simmerling; Bing Wang; Robert J Woods
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

2.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

Review 3.  Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy.

Authors:  Claudia Cerella; Cyril Sobolewski; Mario Dicato; Marc Diederich
Journal:  Biochem Pharmacol       Date:  2010-07-06       Impact factor: 5.858

4.  Identification of potential inhibitors for Klebsiella pneumoniae carbapenemase-3: a molecular docking and dynamics study.

Authors:  Kullappan Malathi; Anand Anbarasu; Sudha Ramaiah
Journal:  J Biomol Struct Dyn       Date:  2019-01-11

5.  Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.

Authors:  Allan Patrick G Macabeo; Warren S Vidar; Xinyu Chen; Michael Decker; Jörg Heilmann; Baojie Wan; Scott G Franzblau; Elano V Galvez; Ma Alicia M Aguinaldo; Geoffrey A Cordell
Journal:  Eur J Med Chem       Date:  2011-04-19       Impact factor: 6.514

6.  Antibacterial activity of flavonoid isolated from Trianthema decandra against Pseudomonas aeruginosa and molecular docking study of FabZ.

Authors:  Rajarathinam Geethalakshmi; Jagadish Chandrabose Sundaramurthi; Dronamraju V L Sarada
Journal:  Microb Pathog       Date:  2018-05-12       Impact factor: 3.738

7.  Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics.

Authors:  A M U B Mahfuz; Felipe Stambuk Opazo; Luis F Aguilar; Muhammad Nasir Iqbal
Journal:  J Biomol Struct Dyn       Date:  2020-11-30

8.  Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships.

Authors:  Afshin Zarghi; Sara Arfaei
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

9.  Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer Membrane Barrier by Host Innate Immune Molecules.

Authors:  Samuel I Miller
Journal:  mBio       Date:  2016-09-27       Impact factor: 7.867

10.  Antitubercular and cytotoxic polyoxygenated cyclohexane derivatives from Uvaria grandiflora.

Authors:  Allan Patrick G Macabeo; Angeli Izza G Flores; Rey Arturo T Fernandez; Simon Budde; Christian Faderl; Hans-Martin Dahse; Scott G Franzblau
Journal:  Nat Prod Res       Date:  2020-03-23       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.